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Introduction
Skeletal muscle mass and fi ber size is dynamically responsive to changes in workload that lead to increased muscle mass and strength. In contrast, muscle atrophy leads to signifi cant weakness in many infl ammatory and infectious diseases, cancer, and human aging. Myopathies are muscle disorders characterized by atrophy of skeletal muscle. Proteins that regulate muscle hypertrophy are much sought after as therapeutic targets for reducing the debilitating effects of muscle atrophy and myopathies ( Patel and Muntoni, 2004 ) .
Four-and-a-half LIM protein 1 (FHL1; also named SLIM1 or KyoT1) belongs to the FHL protein family that comprises four and a half Lin-11, Isl-1, and Mec-3 (LIM) domains. FHL LIM domains mediate protein -protein interactions, scaffolding signaling proteins in the cytoplasm, and transcription factors in the nucleus ( McGrath et al., 2003 ( McGrath et al., , 2006 Cottle et al., 2007 ) . Three FHLs are expressed in skeletal muscle: FHL1, -2, and -3. There are no reports of FHL2 or 3 functioning to regulate skeletal muscle mass; rather, FHL2 regulates bone density ( Gunther et al., 2005 ) , and in muscle cell lines, FHL3 inhibits differentiation ( Cottle et al., 2007 ) . FHL2 and 3 function as transcriptional corepressors and/or coactivators ( Johannessen et al., 2006 ; Cottle et al., 2007 ) ; however, FHL1 transcriptional targets and function in skeletal muscle are largely uncharacterized. Several lines of evidence support an association between FHL1 expression and hypertrophy. FHL1 mRNA is up-regulated during embryonic skeletal muscle development ( Loughna et al., 2000 ) , increasing with postnatal skeletal muscle growth 10-to 15-fold, and also increasing two-to threefold in stretch-induced muscle hypertrophy ( Morgan et al., 1995 ; Morgan and Madgwick, 1999 ;  R egulators of skeletal muscle mass are of interest, given the morbidity and mortality of muscle atrophy and myopathy. Four-and-a-half LIM protein 1 (FHL1) is mutated in several human myopathies, including reducing-body myopathy (RBM). The normal function of FHL1 in muscle and how it causes myopathy remains unknown. We fi nd that FHL1 transgenic expression in mouse skeletal muscle promotes hypertrophy and an oxidative fi ber-type switch, leading to increased whole-body strength and fatigue resistance. Additionally, FHL1 overexpression enhances myoblast fusion, resulting in hypertrophic myotubes in C2C12 cells, (a phenotype rescued by calcineurin inhibition). In FHL1-RBM C2C12 cells, there are no hypertrophic myotubes. FHL1 binds with the calcineurinregulated transcription factor NFATc1 (nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 1), enhancing NFATc1 transcriptional activity. Mutant RBM-FHL1 forms aggregate bodies in C2C12 cells, sequestering NFATc1 and resulting in reduced NFAT nuclear translocation and transcriptional activity. NFATc1 also colocalizes with mutant FHL1 to reducing bodies in RBMaffl icted skeletal muscle. Therefore, via NFATc1 signaling regulation, FHL1 appears to modulate muscle mass and strength enhancement. Loughna et al., 2000 ) . Conversely, FHL1 mRNA decreases during disuse-induced muscle atrophy ( Loughna et al., 2000 ) . However, whether FHL1 itself directly promotes skeletal muscle hypertrophy or whether FHL1 mRNA increases as a consequence of hypertrophy is unknown.
Recently, FHL1 mutations have been identifi ed in three human myopathies, including an X-linked, recessive, adultonset scapuloperoneal myopathy called XMPMA, which presents with postural muscle atrophy and a bent spine, with pseudohypertrophy of other muscles ( Windpassinger et al., 2008 ) ; an X-linked dominant scapuloperoneal syndrome associated with muscle atrophy but no pseudohypertrophy ( Quinzii et al., 2008 ) ; and third, the most severe myopathy, a sporadic or familial reducing body myopathy (RBM; Schessl et al., 2008 ) . Clinical severity in RBM ranges from early childhood-onset muscle weakness followed rapidly by death caused by respiratory failure to adult-onset muscle weakness with slower but relentless progression ( Brooke and Neville, 1972 ; Kiyomoto et al., 1995 ; Figarella-Branger et al., 1999 ; Liewluck et al., 2007 ) . RBM muscle shows cytoplasmic inclusions (reducing bodies), which contain aggregates proposed to arise from the accumulation of misfolded proteins ( Liewluck et al., 2007 ) . The molecular mechanisms by which FHL1 mutations contribute to RBM or other myopathies remain unknown.
Here, we have investigated the role FHL1 plays in regulating postnatal skeletal muscle growth by generating transgenic mice that ectopically express FHL1 in skeletal muscle. These mice exhibit skeletal muscle hypertrophy, with increased wholebody strength. Regulation of calcineurin/nuclear factor of activated T cells (NFAT) signaling may benefit select types of muscular dystrophy St-Pierre et al., 2004 ; Parsons et al., 2007 ) . We identify NFATc1 as a transcriptional target of FHL1. Wild-type FHL1, but not FHL1 mutants associated with RBM, enhanced NFATc1 transcriptional acti vity. RBM mutant FHL1 sequestered NFATc1 to reducing-body aggregates, leading to its decreased nuclear translocation in response to calcineurin activation. Therefore, FHL1 functions to increase skeletal muscle mass, and its loss of function and/or misfolding in RBM may sequester and trap its transcriptional targets to reducing-body aggregates. These studies identify FHL1 as a potential therapeutic target for increasing skeletal muscle mass in human myopathies.
Results

FHL1 promotes myoblast fusion and myotube hypertrophy
Differentiation of skeletal myoblasts (myogenesis) is defi ned by an ordered series of events ( Abmayr et al., 2003 ) . After induction of differentiation, myoblasts withdraw from the cell cycle, then elongate, align, and fuse to form primary multinucleated myotubes. A second wave of myoblast fusion results in further myonuclei addition to nascent myotubes, followed by the assembly of myofi brillar proteins into the costamere and sarcomere ( Sanger et al., 2002 ) . We have previously demonstrated that FHL1 promotes myoblast elongation in Sol8 myoblast cell lines ( McGrath et al., 2003 ) and is important for sarcomere for- blast fusion to form myotubes, and expression persists in adult muscle ( Cox et al., 1990 ) in the elongated postmitotic cells of the somites, as well as in adult mature myofi bers, but not satellite cells ( Gunning et al., 1987 ; Miniou et al., 1999 ; Shen et al., 2003 ) . FHL1 transgenic mice were generated and two lines were characterized. Transgenic HA-FHL1 expression was restricted to skeletal muscle, most prominent in fast-twitch enriched muscles including gastrocnemius ( Fig. 3, B and C , GAS), extensor digitorum longus (EDL), plantaris, extensor carpi ulnaris (ECU), and fl exor digitorum profundus (FDP), which is consistent with HSA promoter activity ( Tinsley et al., 1996 ) , with no expression in other tissues ( Fig. 3 D ) . FHL1 transgenic sarcomere structure appeared undisturbed, with normal ␣ -actinin localization at the Z-line (Fig. S1 , A and B, available at http://www.jcb.org/cgi/content/full/jcb.200804077/DC1). HA-FHL1 colocalized with endogenous FHL1 at the I-band ( Fig. 3 E ; McGrath et al., 2006 ) . FHL1 transgenic gastrocnemius muscle exhibited a signifi cant increase in the total fi ber cross-sectional area (CSA) at both 6 (1.2-fold; Fig. 4 , A and B ) and 12 weeks of age (not dep icted). [ I D ] F I G 4 [ / I D ] Analysis of gastrocnemius fi ber diameters revealed an increase in the frequency of larger fi bers ( ≥ 50 μ m) in transgenic mice ( Fig. 4 C ) . Myofi brils from FHL1 transgenic mice were signifi cantly wider (1.3-fold) than the wild type (Fig. S1 C; Rosenblatt and Woods, 1992 ) . Therefore, FHL1 induces skeletal muscle hypertrophy in vivo. Skeletal muscle hypertrophy can be accompanied by a fi ber type conversion ( Dunn et al., 1999 ) , identifi ed by scoring MHC isoform expression. A 10% increase in oxidative type 2A, MHC-positive fi bers was detected in FHL1 transgenic FDP muscle, with a corresponding decrease in 2X fi bers; however, this latter trend was not statistically signifi cant ( Fig. 4 D ) . No difference was detected in the frequency of type 2B ( Fig. 4 D ) or type 1 fi bers in FHL1 transgenic FDP muscle (not depicted); however, the FDP is composed of < 1% of type 1 fi bers. Therefore, FHL1 promotes skeletal muscle hypertrophy associated with a switch toward oxidative fi ber type expression. myoblast differentiation ( Sabourin et al., 1999 ; Erbay et al., 2003 ) . Normally, this does not exceed ‫ف‬ 50% ( Yoshida et al., 1998 ) . HA-FHL1 myotubes exhibited a similar differentiation index to HA-␤ gal myotubes up until 72 h, but then increased approximately twofold at 96 h ( Fig. 2 C ) . Myoblast fusion was scored as total nuclei per MHC-positive myotube ( Sabourin et al., 1999 ) . After a 96-h differentiation, HA-FHL1 cell lines showed enhanced cell fusion ( Fig. 2 D ) . Therefore, FHL1 may promote myoblast fusion. We detected no changes in the levels or temporal appearance of the muscle regulatory factors MyoD, Myf5, or myogenin in FHL1-expressing cells during differentiation ( Fig. 2 E ) . However, a fi vefold increase in MHC expression was detected in FHL1-expressing cells at 48 h of differentiation ( Fig. 2 , E and F ). Expression of MHC is induced during the latter stages of myoblast differentiation ( Cole et al., 1993 ) ; however, accretion of this major myofi brillar protein is also indicative of muscle anabolism and hypertrophy ( Furmanczyk and Quinn, 2003 ) . Analysis of the protein/DNA ratios in FHL1expressing myotubes compared with controls revealed a twofold increase in protein synthesis relative to DNA, a feature of skeletal muscle hypertrophy ( Fig. 2 G ; De Arcangelis et al., 2005 ) . These studies reveal that FHL1 increases the fusion of myoblasts. The increased protein/DNA ratio coupled with evidence of MHC accretion may be indicative of myotube hypertrophy. An imbalance in the nuclear/cytoplasmic ratio caused by hyperfusion may lead to an increase in protein translation, which increases the myotube cytoplasmic volume ( Adams, 2006 ; .
FHL1 induces skeletal muscle hypertrophy and increased strength
We next investigated whether FHL1 expression in postmitotic myofi bers induced skeletal muscle hypertrophy in vivo. The FHL1 cDNA was fused to an HA tag (HA-FHL1) and linked to the human skeletal muscle ␣ -actin (HSA) promoter ( Fig. 3 A ) , which drives skeletal muscle -specifi c expression ( Brennan and Hardeman, 1993 ) . [ I D ] F I G 3 [ / I D ] Skeletal ␣ -actin is expressed only after myo- Figure 1 . FHL1 induces formation of hypertrophic myotubes, dependent upon calcineurin signaling. C2C12 myoblasts were transiently transfected with HA-␤ gal control (A, B, and E) or HA-FHL1 (C, D, and F), and left untreated (A -D) or treated with the calcineurin inhibitor CsA (E and F) before and during induction of differentiation in low serum media for 96 h. Transfected cells were detected using an HA antibody (green) and costained with propidium iodide (red) to identify nuclei. Cells were visualized using laser scanning confocal microscopy. Arrows indicate hypertrophic myotubes. Bars, 100 μ m. .org/cgi/content/full/jcb.200804077/DC1). The total number of fi bers in the FDP and EDL muscles was not altered (unpublished data). Therefore, the skeletal muscle hypertrophy observed in FHL1 transgenic mice is caused by an increase in the muscle fi ber size, rather than hyperplasia, or an increase in frequency of naturally occurring larger (type 2B) fi bers.
Analysis specifi cally of type 2B fi ber diameters, which were expressed at equivalent frequencies in both FHL1 transgenic and wild-type mice ( Fig. 4 D ) , identifi ed an increase in the frequency of larger ( ≥ 50 μ m) fi bers, with a corresponding decrease in smaller ( ≤ 30 μ m) fi bers in both the FDP ( Fig. 4 , E and F ) and EDL muscle ( Fig. S2 , available at http://www.jcb (B) Skeletal muscle lysates were immunoblotted for HA-FHL1 or ␤ -tubulin in wild-type (WT) or FHL1 transgenic (TG) muscle (GAS, gastrocnemius; EDL, extensor digitorum longus; SOL, soleus plantaris; PLA, plantaris; ECU, extensor carpi ulnaris; FDP, fl exor digitorum profundus). A lysate prepared from C2C12 cells transfected with HA-FHL1 was used as a positive control (+). (C) The relative expression of HA-FHL1 was determined by densitometry of HAimmunoreactive polypeptides, standardized relative to ␤ -tubulin loading. HA-FHL1 expression is represented as a fold difference, relative to GAS, arbitrarily defi ned as one. Graph depicts mean ± SEM (GAS, EDL, SOL, and PLA: n = 3 mice; ECU and FDP: ***, P < 0.005; n = 1 mouse). (D) Tissue lysates from WT or TG mice were immunoblotted for HA-FHL1 using anti-HA antibodies or ␤ -tubulin. Lysates prepared from C2C12 cells transfected with HA-FHL1 were used as a positive control (+). (E) Longitudinal gastrocnemius muscle sections from WT or FHL-TG mice were stained with anti-FHL1 (green) or anti-HA (red) antibodies and imaged by confocal microscopy, then images were further resolved by deconvolution. Bars, 5 μ m. Typically, the nuclei in adult muscle fi bers reside at the fi ber periphery. Nuclei located at the center of the fi ber refl ect satellite cell fusion with existing myofi bers. A 2.1-fold increase in Pax-7 (a satellite cell marker)-positive nuclei ( Fig. 4 G ) and an increase in the number of centralized nuclei were detected in FHL1 transgenic mice at 6 and/or 12 wk, in both gastrocnemius (1.8-fold) and FDP (3.3-fold) muscles ( Fig. 4, H and I ) . Satellite cells may be activated in both compensatory hypertrophy and extreme hypertrophy. The FHL1 transgene was expressed using the HSA promoter, which is active in muscle fi bers in the mouse but not in satellite cells ( Gunning et al., 1987 ; Miniou et al., 1999 ; Shen et al., 2003 ) . Therefore, the increase in satellite cells in FHL1 transgenic muscle must be caused by a stimulatory effect of FHL1 overexpression in myofi bers.
Next, we determined whether FHL1-induced skeletal muscle hypertrophy could enhance muscle strength. A standard whole-body strength test was performed, which measures overall strength of the limb and abdominal muscles . 12-wk-old mice were initially evaluated; however, all mice showed a 100% pass rate. Signifi cantly, mature (12-mo old) FHL1 transgenic mice exhibited a 7.4-fold increase in wholebody strength relative to wild-type mice ( Fig. 4 J ) , which indicates that FHL1 expression can enhance skeletal muscle strength in mature mice.
The muscle contractile properties of the EDL (Table S1 , available at http://www.jcb.org/cgi/content/full/jcb.200804077/DC1) and soleus (not depicted) were examined but showed no difference between FHL1 transgenic versus wild-type mice for twitch or tetanic force when normalized to the CSA. Also, the rate of force production or relaxation was unaltered, perhaps because of the increased type 2A fi bers ( Fig. 4 D ) , which are slow to relax. Therefore, the increased whole-body strength exhibited by transgenic mice is a consequence of muscle hypertrophy and not increased myosin power stroke. In addition, greater fatigue resistance was detected in EDL transgenic muscle ( Fig. 4 K ) , which exhibited skeletal muscle hypertrophy (Fig. S2 ). This may be caused by the increase in oxidative type 2A fi bers observed in FHL1 transgenic mice ( Fig. 4 D ) . In the soleus muscle, no difference was detected (unpublished data). However, the soleus showed low HA-FHL1 expression ( Fig. 3, B and C ) and did not exhibit hypertrophy (not depicted). Therefore, FHL1 induces skeletal muscle hypertrophy, increased muscle strength, and decreased susceptibility to fatigue.
Wild-type FHL1 binds NFATc1, and FHL1
RBM-associated mutants demonstrate reduced NFATc1 binding
The FHL proteins play critical roles as transcriptional coactivators or repressors ( Johannessen et al., 2006 ; Cottle et al., 2007 ) .
Calcineurin signaling is implicated in regulating myopathyrelated muscle degeneration, positively in some myopathies and negatively in others St-Pierre et al., 2004 ; Parsons et al., 2007 ) . Calcineurin is a calmodulindependent, calcium-activated protein phosphatase. Once activated, calcineurin dephosphorylates cytosolic NFAT transcription factors, exposing a nuclear localization sequence and thereby promoting their nuclear translocation and transcriptional events. NFATc1-c3 and NFAT5 are expressed in skeletal muscle ( Abbott et al., 1998 ; . NFATc1 promotes skeletal muscle hypertrophy and oxidative myofi ber-type identity ( Chin et al., 1998 ; Semsarian et al., 1999b ) , NFATc2 governs myofi ber number ( Horsley et al., 2001 ) , and NFATc3 regulates primary myotube formation during myogenesis . NFAT5 is a constitutively nuclear, calcineurin-independent transcription factor, which regulates skeletal muscle cell migration and differentiation . As FHL1 promoted hypertrophy and fi ber type switching in vivo, which is reminiscent of NFATc1 function, we evaluated whether FHL1 interacted with NFATc1. GST-FHL1 bound His-NFATc1 in purifi ed component binding studies ( Fig. 5 A ) .
In control studies, GST -GATA-2 complexed with His-NFATc1 as described previously . Also, GST-FHL1, but not GST-coupled glutathione-Sepharose, incubated with skeletal muscle lysate pulled down an ‫ف‬ 100-kD polypeptide that corresponds to endogenous NFATc1 ( Fig. 5 B ) . We next asked whether FHL1-RBM mutants could also complex with NFATc1. C2C12 myoblasts were cotransfected with myc-NFATc1 and HA-FHL1 (wild type), HA-FHL1 C132F , or HA-FHL1 H123Y . HA-FHL1 was detected in myc-NFATc1 immunoprecipitates ( Fig. 5 C ) . In contrast, binding of RBM-FHL1 mutants to myc-NFATc1, although evident ( Fig. 5 C ) , was reduced by ‫ف‬ 80% ( Fig. 5 D ) . Mutant FHL1 is sequestered to reducing body aggregates in the skeletal muscle of RBM-affected individuals ( Schessl et al., 2008 ) . Therefore, the RBM mutant FHL1 -NFATc1 complex may be less accessible for immunoprecipitation because of its sequestration in reducing body aggregates. To investigate this possibility, we examined the effect of wild-type or RBM mutant FHL1 on the subcellular localization of NFATc1; the latter has been found to localize to the myotube cytosol, and in response to calcineurin activation, in some but not all nuclei ( Abbott et al., 1998 ) . In differentiated C2C12 cells, wild-type HA-FHL1 and myc-NFATc1 colocalized in the cytosol ( Fig. 6 A ) . [ I D ] F I G 6 [ / I D ] FHL1 C132F and FHL1 H123Y localized diffusely in the cytosol but also in perinuclear cytoplasmic aggregates ( Fig. 6 A , white arrowheads), which stained with the reducing body marker menadione -nitro blue tetrazolium chloride (NBT) in the absence of substrate ( Fig. 6 A , black arrowheads), consistent with fi bers; one fi ber is outlined per image. Bars, 40 μ m. (F) The diameters of FDP-2B fi bers from WT versus TG mice are shown ( n = 3 -4 mice; *, P < 0.05). (G) The frequency of Pax-7 -positive nuclei in the gastrocnemius was scored, relative to total nuclei. The bar graph represents the frequency of Pax-7 -positive nuclei for WT and TG mice ( n = 3 -5 mice; **, P < 0.01). (H) Transverse FDP sections were hematoxylin and eosin stained. Arrows indicate centralized nuclei. Bars, 40 μ m. (I) The frequency of centralized nuclei were scored, relative to total myofi ber nuclei, in transverse gastrocnemius and FDP sections ( n = 4 -6 mice; *, P < 0.05; ***, P < 0.001). (J) A whole animal strength test measured overall limb and abdominal strength as a percentage pass rate over 15 trials for WT versus TG 12-mo-old mice ( n = 4 -8; **, P < 0.01). All graphs represent mean ± SEM; WT, white; TG, gray. (K) Muscle fatigability was assessed as a drop in force with repeated tetanic contractions in EDL muscles from WT (black) versus TG (red) mice, expressed as a percentage of initial contraction over time, mean ± SEM ( n = 7, P < 0.02).
( Fig. 6, C and D ) . In contrast, NFATc1 nuclear localization was signifi cantly reduced by HA-FHL1 C132F or HA-FHL1 H123Y coexpression, revealing that RBM-FHL1 mutants may sequester NFATc1 to reducing bodies and therefore reduce NFATc1 activity in the nucleus.
Wild-type FHL1, but not RBM-associated FHL1 mutants, coactivate NFATc1mediated transcription FHL1 mutations have been identifi ed in patients with RBM that occur in critical residues within the second LIM domain (C132F or H123Y) and have been predicted to disrupt folding of the LIM domain, and, therefore, impair protein binding ( Fig. 3 A ; reducing-body aggregates in RBM skeletal muscle ( Schessl et al., 2008 ) . Interestingly, NFATc1, when coexpressed with HA-FHL1 C132F or HA-FHL1 H123Y but not wild-type FHL1, also localized to reducing body aggregates ( Fig. 6 A , insets) . We obtained muscle biopsies from individuals with RBM and examined NFATc1 localization, revealing its reducing body aggregate colocalization with FHL1 ( Fig. 6 B , arrowheads) . We also determined the affect of FHL1-RBM mutants on NFATc1 nuclear translocation in response to the Ca 2+ ionophore, ionomycin, which activates calcineurin signaling ( Abbott et al., 1998 ) . NFATc1 nuclear translocation was detected in 35% of myotube nuclei scored after ionomycin pretreatment, and this localization was not affected by FHL1 coexpression sis confi rmed equal expression of wild-type and mutant FHL1 (unpublished data). Therefore, FHL1, but not mutant FHL1 associated with severe RBM, induces hypertrophic myotubes, a phenotype that we have demonstrated is dependent on calcineurin signaling.
We next investigated whether FHL1 binding to NFATc1 regulates NFATc1-dependent transcription. NFATc1 binds the IL-2 promoter, an NFAT-responsive gene in striated muscle ( Ichida and Finkel, 2001 ) . For C2C12 myoblasts grown in serum (growth conditions), the basal IL-2 reporter activity in vectorcontrol cells was increased approximately threefold by coexpression of NFATc1, and further transactivated approximately ninefold by FHL1 ( Fig. 7 C ) . FHL1 C132F and FHL1 H123Y exhibited reduced ability to transactivate NFAT-mediated IL-2 promoter reporter activity. Similarly, after myoblast differentiation, wild-type FHL1 but not RBM-FHL mutants transactivated NFATc1 reporter activity ( Fig. 7 D ) . To determine if this transcriptional activation occurred in vivo, we examined for expression Schessl et al., 2008 ) . To examine the functional consequence of these mutations, C2C12 myoblasts were transiently transfected with HA-FHL1 C132F or HA-FHL1 H123Y , then induced to differentiate, stained with an anti-HA antibody, and imaged using confocal microscopy ( Fig. 7 A ) . [ I D ] F I G 7 [ / I D ] In control studies, myoblasts were transiently transfected with wild-type HA-FHL1 (HA-FHL1-WT; Fig. 7 A ) . As described earlier ( Fig. 1 ) , overexpression of wildtype FHL1 induced the expression of large hypertrophic myotubes. Interestingly, FHL1 C132F did not induce formation of hypertrophic myotubes ( Fig. 7 A ) , which suggests loss of FHL1 function. In addition, C2C12 myotubes expressing FHL1 C132F exhibited an approximately twofold increase in the frequency of smaller diameter ( ≤ 20 μ m) myotubes ( Fig. 7 B ) , which is reminiscent of the cell culture equivalent of muscle atrophy ( Stevenson et al., 2005 ) . Expression of FHL1 H123Y , a mutation associated with a milder clinical phenotype, also induced hypertrophic myotubes; however, the majority of cells differentiated normally ( Fig. 7, A and B ) . In control studies, immunoblot analy- of a calcineurin-responsive gene, GATA-2 ( Musar ò et al., 1999 ) , in transgenic muscle. Although not normally expressed in skeletal muscle, GATA-2 expression is induced in hypertrophic skeletal muscle, where, despite being a transcription factor, it localizes to the sarcolemma ( Paul and Rosenthal, 2002 ) . Significantly, increased GATA-2 was detected in the gastrocnemius of FHL1 transgenic mice ( Fig. 7 E, F ) . Furthermore, in FHL1 transgenic mice, increased GATA-2 was detected at the sarcolemma ( Fig. 7 G ) .
To verify that FHL1 regulates NFATc1 transcriptional activity, the IL-2 promoter luciferase assay was repeated in C2C12 cells under conditions of siRNA-mediated FHL1 knockdown, as described previously ( McGrath et al., 2006 ) . Under growth conditions, FHL1 knockdown reduced NFATc1-dependent gene transcription ‫ف‬ 1.8-fold relative to the siRNA scrambled (control) sequence ( Fig. 7 H ) and threefold under differentiation conditions ( Fig. 7 I ) . FHL1 immunoblot analysis confi rmed FHL1 protein knockdown under growth and differentiation conditions ( Fig. S3 , available at http://www.jcb.org/cgi/content/full/ jcb.200804077/DC1). Therefore, FHL1 is required for effi cient NFATc1-mediated transcriptional activity.
Discussion
FHL1 has recently been identifi ed as the gene mutated in several familial and sporadic human myopathies ( Quinzii et al., 2008 ; Schessl et al., 2008 ; Windpassinger et al., 2008 ) . However, the normal function of FHL1 in skeletal muscle and its molecular targets are largely uncharacterized. The discovery that FHL1 expression increases muscle fi ber size and oxidative slow fi ber type expression, leading to increased muscle strength and endurance, identifi es it as a regulator of skeletal muscle mass. FHL1 complexes with NFATc1, thereby enhancing its transcriptional activity. In contrast, mutant FHL1 proteins that cause RBM sequestered NFATc1 to reducing body aggregates, resulting in decreased NFATc1 nuclear translocation and transcriptional activity. Collectively, the data presented here provide evidence for a role for FHL1 in regulating skeletal muscle mass via regulation of NFATc1 transcriptional activity ( Fig. 8 ) 
. [ I D ] F I G 8 [ / I D ]
FHL1 transgenic mice exhibited skeletal muscle hypertrophy rather than hyperplasia, showing a ‫ف‬ 20% increase in fi ber size but no change in fi ber number. However, this was insufficient to increase overall muscle weight relative to body weight (unpublished data). The increase in muscle fi ber size in FHL1 transgenic mice induced an approximately sevenfold increase in whole-body strength, with a persistent increase in muscle function, as enhanced muscle strength was observed in 12-mo-old mice. FHL1 induced a fi ber type switch and increased the frequency of centralized myonuclei, which is consistent with hypertrophy. Overexpression of FHL1 also induced myotube hypertrophy in cultured C2C12 cells, as shown by increased myotube size, MHC accretion, and an increased protein/DNA ratio. These results, combined with the severe myopathy observed in individuals with FHL1 mutations, highlight the ability of FHL1 to regulate muscle mass.
Growth factors and increased muscle stretching or loading stimulate satellite cell proliferation and fusion with existing myofi bers, leading to both increased myofi ber size and centralization of myonuclei ( Barton-Davis et al., 1999 ; Paul and Rosenthal, 2002 ) . Hypertrophy is a multistep process and can occur because of expansion of the myofi ber that is driven from within the fi ber through maximized transcription and translation, resulting in increased protein synthesis. Enhanced myoblast differentiation and fusion also contribute to hypertrophy ( Sandri, 2008 ) . FHL1 may facilitate myofi ber hypertrophy via enhanced myoblast fusion, as shown in C2C12 myoblasts and also through a mechanism within the fi ber, as shown by the FHL1 transgenic muscle, in which the HSA promoter sequences Wild-type FHL1 complexes with NFATc1 to increase its transcriptional activity, promoting skeletal muscle hypertrophy and oxidative fi ber type expression. FHL1-RBM mutations sequester NFATc1 into reducing body aggregates, resulting in its reduced nuclear translocation and reduced activation of gene transcription. 0 -20 μ m, > 20 -40 μ m, and > 40 μ m, ± SEM ( n > 300 myotubes from three experiments; n = 3; *, P < 0.05). (C) C2C12 myoblasts were cotransfected with various combinations of expression vectors as indicated, and with NFATc1-dependent ( pGL2-IL-2 ) and Renilla luciferase reporters. Transfected myoblasts were maintained in growth media for 48 h and assayed for luciferase activity. Gal4DBD activity is represented by white bars and Gal4DBD-NFATc1 by gray bars. Error bars represent ± SEM (n ≥ 5 experiments; *, P < 0.05). (D) Transfected myoblasts were differentiated for 48 h and assayed for luciferase activity (48 h; n = 4 experiments). (E) Gastrocnemius (GAS) lysates from wild-type (WT) or HA-FHL1 transgenic (TG) mice were immunoblotted for GATA-2 or ␤ -tubulin (loading control). (F) GATA-2 protein expression levels in WT (white) versus TG (gray) gastrocnemius muscle was quantifi ed using densitometry and standardized to the loading control. The bar graph represents the mean ± SEM ( n = 5 mice per genotype; *, P < 0.05). (G) Transverse gastrocnemius muscle sections were costained with anti -GATA-2 (green), anti-vinculin (red; sarcolemma) antibodies, and To-Pro-3 iodide nuclear stain (blue), then imaged by confocal microscopy. Images were taken at the same intensity. Bars, 40 μ m. (H) C2C12 cells were cotransfected with various combinations of expression vectors for Gal4DBD (white) or Gal4DBD-NFATc1 (gray) and either scrambled (control) or FHL1 siRNA oligonucleotides, as indicated, with NFATc1-dependent ( pGL2-IL-2 ) and Renilla luciferase reporters. Assays were performed under growth conditions. Error bars represent ± SEM ( n = 5 experiments; *, P < 0.05). (I) Luciferase assays performed in H were repeated under differentiation (48 h) conditions ( n = 3 experiments; *, P < 0.05).
RBM may arise from the accumulation of misfolded/unfolded FHL1 protein, ( Meredith, 2005 ; Liewluck et al., 2007 ) . Mutant FHL1 may bind NFATc1 with less affi nity, as suggested by coimmunoprecipitation. Alternatively, the FHL1 -NFATc1 complex is cosequestered to insoluble reducing body aggregates, making it less accessible for immunoprecipitation.
The FHL1 C132F or FHL1 H123Y mutations that cause RBM affect conserved, zinc-coordinating residues located in the second LIM domain. Two other myopathies in which FHL1 is mutated have been described. In one family, a W122S missense mutation was found in the second LIM domain, resulting in adult-onset X-linked dominant scapuloperoneal myopathy ( Quinzii et al., 2008 ) . Reducing bodies were not described in this paper. A third study describes a C224W missense mutation in the FHL1 fourth LIM domain and an isoleucine insertion between residue 127 and 128 in the second LIM domain. These mutations are both associated with a clinical presentation comprising adult-onset X-linked recessive disorder with hypertrophy of type 2 fi bers, leading to pseudo-athleticism with atrophy of type 1 fi bers, associated with postural atrophy and bent spine (XMPMA; Windpassinger et al., 2008 ) . Whether these mutations also cause alteration in calcineurin -NFAT signaling is the subject of ongoing studies. These studies collectively describe seven distinct FHL1 mutations in sporadic and inherited myopathies, which lead to distinct phenotypes.
The calcineurin -NFAT pathway promotes muscle regeneration in some human myopathies ( Sakuma et al., 2003 ) . Calcineurin stimulation can ameliorate dystrophic pathology and myofi ber atrophy, whereas a blockade of calcineurin signaling severely compromises muscle regeneration in mdx dystrophic mice . Genetic disruption of calcineurin improves the muscle pathology in ␦ -sarcoglycannull mice, a mouse model of limb girdle muscular dystrophy-2F ( Parsons et al., 2007 ) , which implies a functional link between calcineurin -NFAT signaling and dystrophy/myopathy. We predict in RBM that the cosequestration of NFATc1 with mutant FHL1 to reducing bodies leads to loss of FHL1 function in enhancing muscle mass and impairs calcineurin -NFATc1 signaling.
In summary, we have identifi ed FHL1 as a novel regulator of skeletal mass. FHL1 binds and regulates NFATc1 transcriptional activity, and this signaling complex is mislocalized into cytoplasmic aggregates in RBM. FHL1 may therefore represent a novel therapeutic target for increasing skeletal muscle mass in myopathies and conditions associated with muscle atrophy.
Materials and methods
Constructs pCGN-FHL1 (human cDNA, GenBank/EMBL/DDBJ accession no. NM_001449 ), pGEX-5 × 1-FHL1, and pCGN-␤ gal (vector control) have been de scribed previously ( McGrath et al., 2003 ( McGrath et al., , 2006 . pCMX and G5E1b-LUC vectors were gifts from R. Schule, (University of Freiburg, Freiburg, Germany). Mouse NFATc1 cDNA (GenBank/EMBL/DDBJ accession no. NM_016791 ) was PCR amplifi ed from GFP-RV-DV-NFATc1 (plasmid 11101; Addgene; Table  S2 , available at http://www.jcb.org/cgi/content/full/jcb.200804077/DC1; Monticelli and Rao, 2002 ) , and cloned into pCMX; pET-30a(+) (Novagen) and pEFBOS (provided by T. Wilson, the Walter and Eliza Hall Institute of Medical directed FHL1 expression in postmitotic myofi bers. The observed increase in the frequency of centralized myonuclei in FHL1 transgenic skeletal muscle is consistent with enhanced fusion of activated satellite cells.
After dephosphorylation by calcineurin, NFATs translocate to the nucleus and activate or repress target genes ( Horsley and Pavlath, 2002 ) . Skeletal muscle electrical activity also promotes NFATc1 nuclear entry via calcineurin activation; however, NFATc1 can also shuttle in and out of the nucleus in the absence of calcineurin activation ( Shen et al., 2006 ) . Calcineurin signaling is proposed to regulate skeletal muscle fi ber type switching ( Chin et al., 1998 ; Naya et al., 2000 ) . Early studies suggested calcineurin could induce skeletal muscle hypertrophy ( Dunn et al., 1999 ; Semsarian et al., 1999b ) . However, transgenic mice expressing constitutively active calcineurin A ␣ (CnA ␣ ) in skeletal muscle do not exhibit hypertrophy ( Naya et al., 2000 ) , and gene-targeted deletion of specifi c calcineurin-isoforms (CnA ␣ or CnA ␤ ) does not lead to changes in myofi ber diameter ( Parsons et al., 2004 ) . Calcineurin inhibition with high doses of CsA, which inhibits activation of most calcineurin isoforms, reduces overload-induced skeletal muscle hypertrophy. This suggests that global inhibition of all calcineurin activity may inhibit hypertrophy ( Dunn et al., 1999 ) . The calcineurin -NFAT pathway also promotes myoblast fusion to myotubes by enhancing IL-4 transcription ( Fornaro et al., 2006 ) .
We propose that FHL1 increases in muscle mass are a consequence of enhancing NFAT transcriptional activity. FHL1 promotes hyperfusion of C2C12 myoblasts, reversed by inhibition of the calcineurin -NFAT pathway. FHL1 transgenic muscle showed a muscle fi ber type switch, which is consistent with calcineurin -NFAT activation, and increased expression of the calcineurin-responsive gene, GATA-2. NFATc2 is critical for sec ondary myogenesis, specifi cally the fusion of myoblasts with existing myotubes/myofi bers ( Horsley et al., 2001 ) . NFATc2 knockout mice exhibit reduced muscle mass, a decrease in myofi ber CSA, and reduced myonuclei number. Myoblast fusion occurs through an ordered series of events, which includes myoblast elongation, alignment, and fusion ( Abmayr et al., 2003 ) . We found that FHL1 promotes the hyper-elongation of myoblasts in an integrin-dependent manner ( McGrath et al., 2003 ) . Myoblast elongation is a critical step before myoblast fusion ( Straube and Merdes, 2007 ; Fortier et al., 2008 ) . The ability of FHL1 to promote myoblast elongation may contribute to the observed hyperfusion effect.
RBM occurs because of mutations in FHL1, which lead to muscle atrophy ( Schessl et al., 2008 ) . FHL1 C132F and FHL1 H123Y RBM mutants exhibited reduced NFATc1-mediated transcriptional activation, and unlike wild-type FHL1, do not induce hypertrophic myotubes. NFATc1 colocalized with mutant FHL1 to reducing body aggregates both in myotubes and in muscle from affl icted RBM individuals. When expressed with FHL1-RBM mutants, NFATc1 showed reduced nuclear translocation in response to calcineurin activation. These results suggest that mutant FHL1 contributes to RBM by reducing NFATc1-dependent transcription of genes that promote hypertrophy or regeneration. The reducing bodies that defi ne FHL1 IN MUSCLE HYPERTROPHY AND MYOPATHY • Cowling et al.
software (version 1.34; National Institutes of Health) . Alternatively, transverse FDP sections were placed on poly-L -lysine -precoated glass microscope slides, then air-dried, fi xed, and stained with hematoxylin and eosin, and FDP fi bers with centralized nuclei within the entire muscle section were counted.
Transverse human muscle sections were prepared, fi xed, stained, and viewed as described previously ( Schessl et al., 2008 ) . Informed consent from human subjects was obtained (Institutional Review Board [IRB] approval 2002 -6-2846 and IRB approvals at the collaborating institutions).
Single myofi brils were isolated from mouse skeletal muscle, then fi xed and stained as described previously ( Knight and Trinick, 1982 ; McGrath et al., 2006 ) . Myofi brils were viewed using a FV1000 laser scanning confocal microscope (Olympus). Widths of 20 myofi brils per mouse were measured using ImageJ software.
Muscle fi ber diameter and area
CSA and minimum diameter were analyzed in gastrocnemius and FDP mouse skeletal muscle. Transverse 8-μ m sections were prepared as described previously ( McGrath et al., 2006 ) and viewed using a laser scanning confocal microscope (TCS NT; Leica). CSA ( μ m 2 ) and fi ber diameter were calculated (gastrocnemius muscle had > 500 fi bers, all fi bers in the FDP) from four to fi ve mice per genotype for wild-type or FHL1 transgenic mice using the analySIS program (Olympus). Alternatively, fi ber diameters were obtained from digital camera images of stained sections using the Image-Pro software (Media Cybernetics). Fiber diameter was determined by measuring the shortest axis for all fi bers within a section to the nearest 10 μ m, as described previously ( Corbett et al., 2001 ) .
Fiber type analysis
Transverse FDP mouse skeletal muscle sections were prepared, fi xed, and stained for MHC isoforms, as described previously ( Corbett et al., 2001 ; Nair-Shalliker et al., 2004 ) . Sections were viewed using a microscope (BX50; Olympus) and captured using a Spot camera (V1.4.0) and Spot software (Diagnostic Instruments, Inc.). Images were collaged together using Photoshop (Adobe). The percentage of type 1, 2A, 2X, and 2B fi bers were calculated in three to fi ve wild-type and FHL1 transgenic mice.
Strength and fatigability test
The whole animal strength and fatigability test was performed on 12-wkand 12-mo-old mice as described previously ( Corbett et al., 2001 ; Joya et al., 2004 ) .
Muscle contractile properties
EDL and soleus muscles were dissected tendon-to-tendon from anaesthetized mice (100 mg/kg BW ketamine and 10 mg/kg BW xylazine) for in vitro contractile measurements. Optimal muscle length (L o ) and maximum isometric tetanic force (P o ) were determined as described previously ( Gregorevic et al., 2004 ) . Stimulus conditions, lever arm control, and contractile data analysis were performed with DMC/DMA computer software (Aurora Scientifi c Inc.). Muscle fatigability was assessed and muscle CSA was determined as described previously ( Gregorevic et al., 2004 ) .
Growth, transient transfection, and immunofl uorescence of C2C12 cells
C2C12 myoblasts were grown, transiently transfected with Lipofectamine 2000, and differentiated when indicated. Cells were then fi xed, permeabilized, blocked, and stained with appropriate nuclear stains and/or antibodies, as described previously ( McGrath et al., 2003 ( McGrath et al., , 2006 Cottle et al., 2007 ) . When required, ionomycin diluted in DMSO was added to each well after 72 h in differentiation media, at a fi nal concentration of 0.5 μ M for 30 min. C2C12 cells were then immediately fi xed and stained as described at the beginning of this paragraph. When required, 5 μ M of CsA was added to C2C12 cells before and continuously during differentiation, as described previously . To measure the myotube diameter, C2C12 cells were transfected as indicated and differentiated for 72 h. The maximum myotube diameter was measured in a total of > 300 myotubes transfected with pCGN-FHL1 constructs from three experiments using ImageJ image analysis software (version 1.34).
For menadione-NBT staining, after immunofl uorescence staining, cells were washed thoroughly with PBS, rinsed briefl y with distilled H 2 O (dH 2 O), and stained with menadione-NBT (0.39 mg/ml menadione and 1 mg/ml NBT in gomori-Tris-HCl buffer, pH 7.4; Sigma-Aldrich) for 20 min at room temperature. Cells were washed with dH 2 O and destained by brief washes in acetone (30%, 60%, 90%, 60%, and 30%) and rinsed again dH 2 O. Samples were viewed using an AX70 microscope fi tted with an Research, Melbourne, Australia). The pGL2-IL-2 promoter -luciferase reporter (plasmid 10959; Addgene; Ichida and Finkel, 2001 ) and pHRLTK (renilla luciferase; Promega) were purchased. To generate pCGN-FHL1-C132F and H123Y, the HindIII to Pst1 fragment of wild-type FHL1 cDNA was excised from pCGN-FHL1 and exchanged for HindIII -Pst1 fragments containing C132F or H123Y mutations ( Schessl et al., 2008 ) . The pcDNA3.1 vector (HSA promoter) has been described previously ( Corbett et al., 2001 ) .
Reagents
Reagents were obtained as follows: C2C12 myoblasts (American Type Culture Collection); Optimem (Invitrogen); Lipofectamine 2000 (Invitrogen); fi bronectin (Sigma-Aldrich); CsA, propidium iodide, and fi bronectin (Sigma-Aldrich); glutathione -Sepharose 4B (GE Healthcare); dual-luciferase reporter assay system (Promega); and To-Pro-3 and the Quant-iT dsDNA assay kit (Invitrogen). ( Bader et al., 1982 ) . Secondary antibodies were as follows: anti -mouse, -rabbit, or -goat conjugated with HRP were obtained from Chemicon; FITC-conjugated anti -rabbit IgG was obtained from Chemicon; and all Alexa-conjugated secondary antibodies were from Invitrogen.
Antibodies
Generation of FHL1 transgenic mice
HA-tagged FHL1 (pCGN vector) was PCR amplifi ed with fl anking EcoRI sites and cloned into the pcDNA3.1+ vector containing an upstream HSA promoter ( Brennan and Hardeman, 1993 ) . The fi nal 3.6-kb construct ( Fig. 1 A ) was excised by Nhe1 -Nae1 digestion, purifi ed, and microinjected into one-cell embryos, then implanted into pseudo-pregnant FVB/n mice. Positive founders were bred to FVB/n wild-type mice, and transgenic mice were selected by PCR analysis (Table S2 ). Animals were housed in a temperature-controlled room (19 -22 ° C) with a 12:12-h light/dark cycle. Unless otherwise stated, all experiments were performed using 6-or 12-wk-old female transgenic mice and wild-type, sex-matched littermate controls, as indicated. Mice were humanely killed by CO 2 inhalation followed by cervical dislocation, according to the National Health and Medical Research Council guidelines (Monash University Animal Ethics no. BAM/2001/22).
Preparation of muscle lysates
The mouse gastrocnemius was dissected, minced, and homogenized on ice for 3 × 30 s (DIAX 900; Heidolph) in 10 times the weight/volume of 1% NP-40 Tris-Cl buffer, pH 8, then extracted for 1 h at 4 ° C. Lysates were centrifuged at 1,000 g for 30 s, and the total cell lysate obtained was stored at Ϫ 80 ° C. Protein concentration was determined using a DC protein assay kit (Bio-Rad Laboratories). 20 -100 μ g of lysate was analyzed by SDS-PAGE and Western blotting.
Histological and immunofl uorescence analysis of skeletal muscle
Longitudinal and transverse cryosections of gastrocnemius, EDL, soleus, and FDP mouse skeletal muscles were prepared, fi xed, stained, viewed, and deconvolved where appropriate, as described previously ( McGrath et al., 2006 ) . To obtain polarized light microscopy images, fi xed longitudinal sections from 12-wk-old male mice were viewed with a microscope (AX70; Olympus). When nuclear staining was required, sections were pretreated with 200 μ g/ml RNase A (Sigma-Aldrich), and nuclei were detected by costaining with To-Pro-3 iodide (Invitrogen) or Dapi (Sigma-Aldrich) for 10 min. The total number of gastrocnemius muscle fi bers with centralized nuclei or Pax-7 -positive nuclei were counted in > 500 fi bers in at least three wild-type and transgenic mice using ImageJ image analysis Image and statistical analysis All microscopy was performed at Monash Microimaging at Monash University, Australia. All samples for microscopy were mounted in SlowFade reagent (Invitrogen) and viewed at room temperature. Confocal microscopy was performed using a confocal laser scanning microscope (TCS/ NT; Leica) on a DMRBE upright microscope. Leica Confocal Software (LCS version 2.5; Leica) was used for confocal image acquisition. Fluorescence and light microscopy was performed using a microscope (AX70 Provis; Olympus) fi tted with either a charge-coupled device (color; DP70; Olympus) or FVII monochrome (black and white; Olympus) camera. AnalySiS software was used for image capture and analysis.
Western blot fi lms were scanned and band signal intensities were determined using a Gel-Pro Analyzer (version 3.1; Media Cybernetics). Densitometry values were expressed as a fold difference relative to the control, standardized to corresponding total actin/ ␤ -tubulin values. All results are presented as the mean ± SE (SEM). Statistical analysis was performed using the unpaired student ' s t test unless stated otherwise. p-values of < 0.05 were considered signifi cant. Fig. S1 shows the normal morphology of the sarcomere and the increased myofi bril width in FHL1 transgenic mice. Fig. S2 shows hypertrophy of type 2B fi bers of the EDL in FHL1 transgenic mice. Fig. S3 shows knockdown of endogenous FHL1 in C2C12 cells using FHL1 siRNA oligonucleotides. Table S1 shows the contractile data from EDL muscles of FHL1 transgenic and wild-type mice. Table S2 shows the sequences of all oligonucleotides used. Online supplemental material is available at http://www.jcb .org/cgi/content/full/jcb.200804077/DC1.
Online supplemental material
